Literature DB >> 28495943

Retention of Gadolinium-Based Contrast Agents in Multiple Sclerosis: Retrospective Analysis of an 18-Year Longitudinal Study.

Y Forslin1,2, S Shams3,2, F Hashim3,2, P Aspelin3,2, G Bergendal3,2,4, J Martola3,2, S Fredrikson4,5, M Kristoffersen-Wiberg3,2, T Granberg3,2.   

Abstract

BACKGROUND AND
PURPOSE: Gadolinium-based contrast agents have been associated with lasting high T1-weighted signal intensity in the dentate nucleus and globus pallidus, with histopathologically confirmed gadolinium retention. We aimed to longitudinally investigate the relationship of multiple gadolinium-based contrast agent administrations to the Signal Intensity Index in the dentate nucleus and globus pallidus and any associations with cognitive function in multiple sclerosis.
MATERIALS AND METHODS: The Signal Intensity Index in the dentate nucleus and globus pallidus was retrospectively evaluated on T1-weighted MR imaging in an 18-year longitudinal cohort study of 23 patients with MS receiving multiple gadolinium-based contrast agent administrations and 23 healthy age- and sex-matched controls. Participants also underwent comprehensive neuropsychological testing.
RESULTS: Patients with MS had a higher Signal Intensity Index in the dentate nucleus (P < .001), but not in the globus pallidus (P = .19), compared with non-gadolinium-based contrast agent-exposed healthy controls by an unpaired t test. Increasing numbers of gadolinium-based contrast agent administrations were associated with an increased Signal Intensity Index in the dentate nucleus (β = 0.45, P < .001) and globus pallidus (β = 0.60, P < .001). This association remained stable with corrections for the age, disease duration, and physical disability for both the dentate nucleus (β = 0.43, P = .001) and globus pallidus (β = 0.58, P < .001). An increased Signal Intensity Index in the dentate nucleus among patients with MS was associated with lower verbal fluency scores, which remained significant after correction for several aspects of disease severity (β = -0.40 P = .013).
CONCLUSIONS: Our data corroborate previous reports of lasting gadolinium retention in brain tissues. An increased Signal Intensity Index in the dentate nucleus and globus pallidus was associated with lower verbal fluency, which does not prove causality but encourages further studies on cognition and gadolinium-based contrast agent administration.
© 2017 by American Journal of Neuroradiology.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28495943      PMCID: PMC7959913          DOI: 10.3174/ajnr.A5211

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  35 in total

Review 1.  The role of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: A critical update.

Authors:  Jean-Marc Idée; Nathalie Fretellier; Caroline Robic; Claire Corot
Journal:  Crit Rev Toxicol       Date:  2014-09-26       Impact factor: 5.635

2.  Gadodiamide and Dentate Nucleus T1 Hyperintensity in Patients With Meningioma Evaluated by Multiple Follow-Up Contrast-Enhanced Magnetic Resonance Examinations With No Systemic Interval Therapy.

Authors:  Carlo Cosimo Quattrocchi; Carlo Augusto Mallio; Yuri Errante; Vincenzo Cirimele; Luciano Carideo; Antonella Ax; Bruno Beomonte Zobel
Journal:  Invest Radiol       Date:  2015-07       Impact factor: 6.016

3.  Gadolinium-based Contrast Agent Accumulates in the Brain Even in Subjects without Severe Renal Dysfunction: Evaluation of Autopsy Brain Specimens with Inductively Coupled Plasma Mass Spectroscopy.

Authors:  Tomonori Kanda; Toshio Fukusato; Megumi Matsuda; Keiko Toyoda; Hiroshi Oba; Jun'ichi Kotoku; Takahiro Haruyama; Kazuhiro Kitajima; Shigeru Furui
Journal:  Radiology       Date:  2015-05-05       Impact factor: 11.105

Review 4.  Magnetic resonance techniques in multiple sclerosis: the present and the future.

Authors:  Massimo Filippi; Maria A Rocca; Nicola De Stefano; Christian Enzinger; Elizabeth Fisher; Mark A Horsfield; Matilde Inglese; Daniel Pelletier; Giancarlo Comi
Journal:  Arch Neurol       Date:  2011-12

5.  Consensus paper: Language and the cerebellum: an ongoing enigma.

Authors:  Peter Mariën; Herman Ackermann; Michael Adamaszek; Caroline H S Barwood; Alan Beaton; John Desmond; Elke De Witte; Angela J Fawcett; Ingo Hertrich; Michael Küper; Maria Leggio; Cherie Marvel; Marco Molinari; Bruce E Murdoch; Roderick I Nicolson; Jeremy D Schmahmann; Catherine J Stoodley; Markus Thürling; Dagmar Timmann; Ellen Wouters; Wolfram Ziegler
Journal:  Cerebellum       Date:  2014-06       Impact factor: 3.847

6.  Macrocyclic and Other Non-Group 1 Gadolinium Contrast Agents Deposit Low Levels of Gadolinium in Brain and Bone Tissue: Preliminary Results From 9 Patients With Normal Renal Function.

Authors:  Nozomu Murata; Luis F Gonzalez-Cuyar; Kiyoko Murata; Corinne Fligner; Russell Dills; Daniel Hippe; Kenneth R Maravilla
Journal:  Invest Radiol       Date:  2016-07       Impact factor: 6.016

7.  Multiple sclerosis: hyperintense dentate nucleus on unenhanced T1-weighted MR images is associated with the secondary progressive subtype.

Authors:  Luca Roccatagliata; Luisa Vuolo; Laura Bonzano; Anna Pichiecchio; Giovanni Luigi Mancardi
Journal:  Radiology       Date:  2009-05       Impact factor: 11.105

8.  High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material.

Authors:  Tomonori Kanda; Kazunari Ishii; Hiroki Kawaguchi; Kazuhiro Kitajima; Daisuke Takenaka
Journal:  Radiology       Date:  2013-12-07       Impact factor: 11.105

9.  Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C.

Authors:  Thomas Frenzel; Philipp Lengsfeld; Heiko Schirmer; Joachim Hütter; Hanns-Joachim Weinmann
Journal:  Invest Radiol       Date:  2008-12       Impact factor: 6.016

Review 10.  25 Years of Contrast-Enhanced MRI: Developments, Current Challenges and Future Perspectives.

Authors:  Jessica Lohrke; Thomas Frenzel; Jan Endrikat; Filipe Caseiro Alves; Thomas M Grist; Meng Law; Jeong Min Lee; Tim Leiner; Kun-Cheng Li; Konstantin Nikolaou; Martin R Prince; Hans H Schild; Jeffrey C Weinreb; Kohki Yoshikawa; Hubertus Pietsch
Journal:  Adv Ther       Date:  2016-01-25       Impact factor: 3.845

View more
  19 in total

Review 1.  Gadolinium Deposition and Liver MRI.

Authors:  Robert M Marks; Ryan M Ash; James T Lee
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-04-13

Review 2.  Gadolinium-based contrast agents - review of recent literature on magnetic resonance imaging signal intensity changes and tissue deposits, with emphasis on pediatric patients.

Authors:  Einat Blumfield; David W Swenson; Ramesh S Iyer; A Luana Stanescu
Journal:  Pediatr Radiol       Date:  2019-03-29

Review 3.  Standardized assessment of the signal intensity increase on unenhanced T1-weighted images in the brain: the European Gadolinium Retention Evaluation Consortium (GREC) Task Force position statement.

Authors:  Carlo C Quattrocchi; Joana Ramalho; Aart J van der Molen; Àlex Rovira; Alexander Radbruch
Journal:  Eur Radiol       Date:  2018-11-09       Impact factor: 5.315

Review 4.  A Review of the Current Evidence on Gadolinium Deposition in the Brain.

Authors:  Richard Pullicino; Mark Radon; Shubhabrata Biswas; Maneesh Bhojak; Kumar Das
Journal:  Clin Neuroradiol       Date:  2018-03-09       Impact factor: 3.649

5.  Signal Hyperintensity on Unenhanced T1-Weighted Brain and Cervical Spinal Cord MR Images after Multiple Doses of Linear Gadolinium-Based Contrast Agent.

Authors:  G Barisano; B Bigjahan; S Metting; S Cen; L Amezcua; A Lerner; A W Toga; M Law
Journal:  AJNR Am J Neuroradiol       Date:  2019-07-25       Impact factor: 3.825

Review 6.  Biological effects of MRI contrast agents: gadolinium retention, potential mechanisms and a role for phosphorus.

Authors:  Joel Garcia; Stephen Z Liu; Angelique Y Louie
Journal:  Philos Trans A Math Phys Eng Sci       Date:  2017-11-28       Impact factor: 4.226

7.  Gadolinium retention after administration of contrast agents based on linear chelators and the recommendations of the European Medicines Agency.

Authors:  Ilona A Dekkers; Rick Roos; Aart J van der Molen
Journal:  Eur Radiol       Date:  2017-10-23       Impact factor: 5.315

8.  Gadolinium Retention in the Brain: An MRI Relaxometry Study of Linear and Macrocyclic Gadolinium-Based Contrast Agents in Multiple Sclerosis.

Authors:  Y Forslin; J Martola; Å Bergendal; S Fredrikson; M K Wiberg; T Granberg
Journal:  AJNR Am J Neuroradiol       Date:  2019-06-27       Impact factor: 3.825

Review 9.  Gadolinium-based contrast agents in children.

Authors:  Michael N Rozenfeld; Daniel J Podberesky
Journal:  Pediatr Radiol       Date:  2018-08-04

Review 10.  Gadolinium Retention: A Research Roadmap from the 2018 NIH/ACR/RSNA Workshop on Gadolinium Chelates.

Authors:  Robert J McDonald; Deborah Levine; Jeffrey Weinreb; Emanuel Kanal; Matthew S Davenport; James H Ellis; Paula M Jacobs; Robert E Lenkinski; Kenneth R Maravilla; Martin R Prince; Howard A Rowley; Michael F Tweedle; Herbert Y Kressel
Journal:  Radiology       Date:  2018-09-11       Impact factor: 11.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.